The purpose of this study is to compare the usual treatment (encorafenib and cetuximab) alone to using nivolumab plus the usual treatment.
Learn more about the S2107 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer.
